EUVIMEDEUVIMED entdecken
Crossref

Utilizzo dei Real World Data per definire la popolazione target di nuove indicazioni terapeutiche: l’esempio delle terapie CAR-T

Michela Servadio, Valeria Belleudi, Marco Finocchietti, Ilaria Cozzi, Marina Davoli, Antonio Addis

Recenti Progressi in Medicina · 2024

DOI: 10.1701/4392.43936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Recenti Progressi in Medicina, 2024. Verfasst von Michela Servadio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di epidemiologia, Servizio sanitario regionale del Lazio, Asl Roma 1. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Immunotherapy, Adoptive.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CAR-T therapies are a form of innovative and personalised immunotherapy in the field of onco-haematology. Diffuse large B-cell lymphoma (DLBCL) is a very aggressive form of non-Hodgkin’s lymphoma (NHL) for which CAR-T therapies are approved as 3rd-line and more recently (from 11/11/2023), as 2nd-line for patients who relapse within 12 months after 1st-line chemo-immunotherapy. This study was conducted to estimate the eligible DLBCL population for CAR-T therapies in 2024 in Lazio region. Starting with a cohort of DLBCL patients from a previous work, a series of proportions were first obtained applying the eligibility criteria for CAR-T, and then applied to the annual incident cases of NHL in Lazio region. From 1,353 NHL cases, 392 (29%) were considered DLBCL of which 82% (322) received first line chemo-immunotherapy. They were then divided into two groups: with relapse ≤12 months (Group 1) and with relapse >12 months (Group 2). Fifty percent of Group 1 (46 cases) and part of those not eligible to ASCT (35%=16 cases) constitute the eligible population for CAR-T therapy as 2nd-line. From the 29 cases of Group 2, were calculated the proportions of CAR-T eligible patients among those not eligible for ASCT (35%=5 cases) and those who did not respond to salvage chemotherapy (65%=4 cases) and with post-transplant relapse (39%=3 cases). A total of 74 DLBCL patients were found to be eligible for CAR-T therapies. This study demonstrates that the use of Real World Data is a valuable tool in defining the target population for new therapeutic indications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseImmunotherapy, AdoptiveHumansMaleFemaleMiddle AgedAgedAdultItalyTime FactorsRecurrence

Autor:innen und Institutionen

  • Dipartimento di epidemiologia, Servizio sanitario regionale del Lazio, Asl Roma 1.

Zitieren

APA

Servadio, M., Belleudi, V., Finocchietti, M., Cozzi, I., Davoli, M., & Addis, A. (2024). Utilizzo dei Real World Data per definire la popolazione target di nuove indicazioni terapeutiche: l’esempio delle terapie CAR-T. Recenti Progressi in Medicina. https://doi.org/10.1701/4392.43936

Vancouver

Servadio M, Belleudi V, Finocchietti M, Cozzi I, Davoli M, Addis A. Utilizzo dei Real World Data per definire la popolazione target di nuove indicazioni terapeutiche: l’esempio delle terapie CAR-T. Recenti Progressi in Medicina. 2024. doi:10.1701/4392.43936

BibTeX
@article{Servadio2024,
  author = {Servadio, Michela and Belleudi, Valeria and Finocchietti, Marco and Cozzi, Ilaria and Davoli, Marina and Addis, Antonio},
  title = {Utilizzo dei Real World Data per definire la popolazione target di nuove indicazioni terapeutiche: l’esempio delle terapie CAR-T},
  journal = {Recenti Progressi in Medicina},
  year = {2024},
  doi = {10.1701/4392.43936}
}
Kostenlos starten →